Natera's Patent Setback: A Bump in the Road?

Natera stock dips after losing key patent claims in a battle with NeoGenomics, but a major clinical trial for its Signatera test offers hope. Is this a minor setback or a sign of deeper trouble for the genetic testing firm? Find out how this legal defeat and promising developments are impacting Natera's volatile stock and future prospects. Hosted on Acast. See acast.com/privacy for more information.